Information Provided By:
Fly News Breaks for October 6, 2016
ALNY, MDCO
Oct 6, 2016 | 07:12 EDT
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
News For MDCO;ALNY From the Last 2 Days
There are no results for your query MDCO;ALNY